ClinicalTrials.gg
Not yet recruitingNCT07797660Updated Sep 1, 2026

A Study for Postoperative Delirium in Older Patients With Intracranial Tumors

An observational study in Delirium and Brain Tumor, sponsored by Beijing Tiantan Hospital. Not yet recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-01.

Sponsored by Beijing Tiantan Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
164
Ages
60 Years and older
Sex
All
01

Study summary

Postoperative delirium is a common acute central nervous system syndrome, which often occurs 1-5 days after surgery. Postoperative delirium can prolong the length of hospital stay, increase the mortality rate, and is also associated with long-term postoperative cognitive dysfunction. However, the pathogenesis of postoperative delirium in elderly patients undergoing neurosurgical procedures, who are at high risk for ostoperative delirium, remains unclear. This study aims to elucidate the underlying mechanisms of postoperative delirium in this population and inform the development of effective prevention and treatment strategies.

02

Conditions studied

  • Delirium
  • Brain Tumor
03

In context

Delirium

933 studies on the registry are indexed under Delirium; 190 are open to participants now.

This study's planned enrollment of 164 is below the median of 194 across 342 observational studies indexed under Delirium.

Browse Delirium studies →

Lead sponsor

Beijing Tiantan Hospital is the lead sponsor of 489 studies on the registry; 293 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will be selected from elderly patients scheduled to undergo elective craniotomy for intracranial tumour resection at Beijing Tiantan Hospital.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients undergoing elective craniotomy for intracranial tumour resection
  • Patients who will provide written

Exclusion criteria

Exclusion Criteria:

  • Patients with severe preoperative cognitive impairment precluding subsequent assessments
  • History of psychotropic medication use
  • Previous history of neurosurgical operation
  • Severe bradycardia (heart rate \< 40 beats per minute)
  • Sick-sinus syndrome or atrioventricular block of grade Ⅱ or above
  • Severe hepatic insufficiency ( grade C)
  • Renal failure requiring renal replacement therapy
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
164 participants (estimated)
Patient registry
No

Groups and cohorts

  • Intraoperative hypotension
  • Without intraoperative hypotension
06

What researchers measure

Primary outcomes

  1. The association between intraoperative hypotension and postoperative delirium

    Intraoperative hypotension was defined by absolute mean arterial pressure (MAP) thresholds (sustained MAP \< 75, 70, 65, or 60 mm Hg for \> 1 min) or relative MAP reductions (10%, 20%, 30%, or 40% below preoperative baseline). The Confusion Assessment Method for the Intensive Care Unit scale (CAM-ICU) or 3 min diagnostic interview for CAM (3D-CAM) will be applied to assess postoperative delirium.

    Time frame: The surgery day and twice a day (from 8:00 to 10:00 and from 18:00 to 20:00) during the first postoperative 5 days.

Secondary outcomes

  1. Characteristic of electroencephalogram

    Electroencephalographic signals will be acquired with the Masimo SedLine® monitor, which will yield the Patient State Index (PSI), burst-suppression ratio, raw EEG traces, density spectral array, spectral edge frequency, and electromyographic data. Frequency bands will be predefined as delta (1-3 Hz), theta (4-7 Hz), alpha (8-12 Hz), and beta (13-40 Hz). Relative power for each band will be computed relative to total spectral power.

    Time frame: The surgery day

  2. Regional cerebral oxygen saturation changes

    Regional cerebral oxygen saturation will be monitored with near-infrared spectroscopy.

    Time frame: The surgery day

  3. Blood inflammatory factors

    Arterial blood (4 mL) will be collected from patients during surgery, and blood inflammatory factors will be measured.

    Time frame: The surgery day

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2027, 12 months later.

Of 176 non-industry observational studies under Delirium, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 178 studies reached it within 20 months; a quarter within 11 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2026
First posted
Sep 1, 2026
StartEst.
Aug 30, 2026
Primary completionEst.
Aug 30, 2027
CompletionEst.
Sep 30, 2027
Last update
Sep 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07797660
Responsible party
Yuming Peng (Deputy chief of Department of Anesthesiology, Beijing Tiantan Hospital) — Principal investigator
First posted
Sep 1, 2026
Start date
Aug 30, 2026 (estimated)
Primary completion
Aug 30, 2027 (estimated)
Completion
Sep 30, 2027 (estimated)
Last update
Sep 1, 2026

Study contacts

Yuming Peng, M.D., Ph.D
Contact
florapym766@163.com
8610-59976658

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion